T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Clorox
CLX
$13.1B
| $491M | 0.11% |
5,368,155
-633,503
| -11% | -$56.7M |
|
227
Walmart Inc
WMT
$901B
| $490M | 0.11% |
19,598,307
-2,003,874
| -9% | -$51.5M |
|
228
RH
RH
$3.46B
| $489M | 0.11% |
5,256,940
+496,900
| +10% | +$34.8M |
|
229
Nucor
NUE
$61.9B
| $485M | 0.1% |
9,839,217
-82,443
| -0.8% | -$4.23M |
|
230
GSK
GSK
$102B
| $483M | 0.1% |
7,231,865
+33,683
| +0.5% | +$2.28M |
|
231
L3Harris
LHX
$53.3B
| $483M | 0.1% |
6,379,760
-8,200
| -0.1% | -$611K |
|
232
Workday
WDAY
$44.8B
| $481M | 0.1% |
5,350,608
+40,861
| +0.8% | +$3.22M |
|
233
Corning
GLW
$137B
| $477M | 0.1% |
21,710,453
-3,511,134
| -14% | -$74.5M |
|
234
Bunge Global
BG
$21.4B
| $475M | 0.1% |
6,280,435
+657,879
| +12% | +$50.9M |
|
|
MWV
235
DELISTED
MEADWESTVACO CORP
MWV
| $472M | 0.1% |
10,661,676
-1,685,886
| -14% | -$68.4M |
|
236
Universal Health Services
UHS
$9.94B
| $467M | 0.1% |
4,875,381
-33,940
| -0.7% | -$2.93M |
|
237
ConocoPhillips
COP
$151B
| $466M | 0.1% |
5,432,607
-68,300
| -1% | -$5.32M |
|
|
SBNY
238
DELISTED
Signature Bank
SBNY
| $466M | 0.1% |
3,689,635
-150,425
| -4% | -$18.1M |
|
239
Autodesk
ADSK
$53.1B
| $465M | 0.1% |
8,254,675
+485,512
| +6% | +$24.6M |
|
|
ETFC
240
DELISTED
E*Trade Financial Corporation
ETFC
| $463M | 0.1% |
21,791,400
-3,617,242
| -14% | -$76M |
|
|
HAR
241
DELISTED
Harman International Industries
HAR
| $463M | 0.1% |
4,308,702
-1,159,779
| -21% | -$123M |
|
242
Zurn Elkay Water Solutions
ZWS
$8.6B
| $461M | 0.1% |
33,987,006
+1,143,337
| +3% | +$15.2M |
|
243
Illumina
ILMN
$29.1B
| $449M | 0.1% |
2,587,876
-169,647
| -6% | -$25.3M |
|
244
Ametek
AME
$58.8B
| $449M | 0.1% |
8,583,924
+7,290
| +0.1% | +$383K |
|
245
Enovis
ENOV
$1.42B
| $448M | 0.1% |
3,492,538
-1,021,497
| -23% | -$128M |
|
|
DISCK
246
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
| $446M | 0.1% |
12,280,302
-20,738,598
| -63% | -$760M |
|
|
ITMN
247
DELISTED
INTERMUNE INC
ITMN
| $443M | 0.1% |
10,042,757
+16,294
| +0.2% | +$600K |
|
248
Elevance Health
ELV
$84.7B
| $443M | 0.1% |
4,113,750
+125,822
| +3% | +$13M |
|
249
Stanley Black & Decker
SWK
$15.7B
| $440M | 0.1% |
5,013,281
+431,904
| +9% | +$36.8M |
|
250
Sensata Technologies
ST
$6.73B
| $436M | 0.09% |
9,324,592
+24,947
| +0.3% | +$1.09M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.